ARK Investment Management LLC Has $9.40 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

ARK Investment Management LLC decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 13,192 shares of the biopharmaceutical company’s stock after selling 1,959 shares during the period. ARK Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $9,397,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in REGN. Rakuten Securities Inc. lifted its position in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. Fairfield Financial Advisors LTD bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $37,000. Private Wealth Management Group LLC lifted its position in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 39 shares in the last quarter. Finally, Truvestments Capital LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $39,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of several research reports. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Morgan Stanley cut their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Barclays reduced their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Bank of America restated an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Up 1.4 %

Regeneron Pharmaceuticals stock opened at $723.47 on Wednesday. The stock has a market cap of $79.09 billion, a P/E ratio of 18.90, a P/E/G ratio of 2.34 and a beta of 0.08. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The company’s 50-day moving average price is $698.84 and its two-hundred day moving average price is $875.48.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $11.86 EPS. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.49%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.